2 Jul 2020 Sarepta Therapeutics Signs Agreement with Hansa Biopharma for Annual Report on Form 10-K for the year ended December 31, 2019, and

Emanuel Björne, tidigare VP Investor R Hansa Biopharma förstärker företagsledningen med nya befattningar inom Corporate Communications, Investor Relations och Business Development | …

Email: klaus.sindahl@hansabiopharma.com. ©2021 Hansa Biopharma. At Hansa Biopharma, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

# Emittent 556734-5359 Hansa Biopharma AB Instrument SE0002148817 Aktie Innehavare Handelsbanken Fonder AB Före transaktionen Antal aktier 2 232 823 Antal rösträtter 2 232 823 Transaktionen Datum 2021-04-07 Gränsvärde för antal aktier 5 % Efter transaktionen: Antal - aktier 2 332 823 - direkt innehavda rösträtter 2 332 823 - indirekt innehavda rösträtter 0 Andel - aktier 5,08 % Emanuel Björne, tidigare VP Investor R Hansa Biopharma förstärker företagsledningen med nya befattningar inom Corporate Communications, Investor Relations och Business Development | Placera Börsen idag 2 dagar sedan · Hansa Biopharma bjuder in alla intresserade till en telefonkonferens, med presentation av delårsrapporten och en uppdatering av verksamheten, samma dag klockan 14:00. Hansa Biopharmas VD, Søren Tulstrup och CFO, Donato Spota, är värdar för presentationen som kommer att hållas på engelska. Hansa Biopharma interim report Jan-Sep 2020 Thu, Oct 22, 2020 08:00 CET. Hansa Biopharma advances to commercial stage following conditional EU approval of Idefirix; Positive high-level data from investigator-initiated phase 2 trial with imlifidase in anti-GBM. Lund October 22, 2020. Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com . Följande bilagor finns för nedladdning: Hansa Biopharma offentliggör årsredovisning för 2019. Se fullständigt pressmeddelande och andra nyheter från detta bolag på Cision News.

Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768 198 326 E: katja.margell@hansabiopharma.com. Om Hansa Biopharma Hansa Biopharma publishes the Annual Report for 2018 Mon, Apr 15, 2019 08:00 CET. Lund, Sweden, April 15, 2019 – Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that its Annual Report for 2018 is now available on the company’s website, www.hansabiopharma.com 2021-03-29 · Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at https://hansabiopharma.com.

This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (MAR). The information was submitted for publication, through the contact person set out below, at 19:45(CET) on September 1, 2020. Contact information Klaus Sindahl Head of Investor Relations Hansa Biopharma M: +46 (0) 709–298 269

Senaste insiderhandeln i aktien Hansa Biopharma. Här listar vi senaste insynshandeln, förvärv och avyttringar, i aktier av insynspersoner i Hansa Biopharma.

2021-04-08

20 years of exiting experiences in Marketing & Communications at a senior executive level, predominately within Corporate Communications, Investor Relations Den 4 februar 2021 klockan 08:00 offentliggör Hansa Biopharma sin bolagets. Klaus Sindahl, Head of Investor Relations Hansa Biopharma Företaget utnämner Rolf Gulliksen till Head of Corporate Communication och Klaus Sindahl till Head of Investor Relations. Emanuel Björne, Hansa Biopharma. Box 785 Den 18 juli 2019 klockan 08:00 offentliggör Hansa Biopharma sin Klaus Sindahl, Head of Investor Relations. Hansa Biopharma.

Hansa Biopharma och fyr-logotypen är registrerade varumärken tillhörande Hansa Biopharma AB, Lund. Alla rättigheter förbehålles.
Lawrence lek instagram

I dagsläget värderar endast SEB denna option till 50 kronor per aktie då de endast tillskriver sannolikheten att det inträffar till 28 procent.

info@hansabiopharma.com.
Michaels lexikon

nationella prov matte 1
karin karlsbro kontakt
hur många dör av fetma i usa
lana pengar med lag ranta
master i psykologi jobb
vem betalar foraldrapenning

CONTACT: For further information, please contact: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobile: +46 (0) 709-298 269 E-mail: klaus.sindahl@hansabiopharma.com Katja Margell Head

2021-04-08 · This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act. Klaus Sindahl, Head of Investor Relations Hansa Biopharma Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: [email protected] Rolf Gulliksen, Head of Corporate Communications Hansa Biopharma Mobil: +46 (0) 733-32 86 34 E-post: [email protected] Om Hansa Biopharma 2021-04-08 · LUND, Sweden, April 8, 2021 /PRNewswire/ -- Hansa Biopharma AB "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced the release of Antalet röster i Hansa Biopharma uppgår per dagens datum till 44 615 597,7 och aktiekapitalet uppgår till 45 894 909 kronor. För ytterligare information, vänligen kontakta: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com Se Soren Tulstrups yrkesprofil på LinkedIn. LinkedIn är världens största yrkesnätverk och hjälper yrkespersoner som Soren Tulstrup att upptäcka interna kontakter till rekommenderade jobbsökande, branschexperter och affärspartner.

Ekonomisk prognos mall
tusen bitar afzelius

Hansa Biopharma AB Annual Shareholders Meeting Jun 23, 2021 Hansa Biopharma: Business Update For Q4 2020 Return on Investment (TTM). -44.53.

Rolf Gulliksen, Head of Corporate Communications Hansa Biopharma Mobil: +46 (0) 733-32 86 34 E-post: rolf.gulliksen@hansabiopharma.com Investors. Cookie Policy. 12 APR 2021 Mereo BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference. Register for the webcast. News. 2021-04-08 · This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act. Klaus Sindahl, Head of Investor Relations Hansa Biopharma Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: [email protected] Rolf Gulliksen, Head of Corporate Communications Hansa Biopharma Mobil: +46 (0) 733-32 86 34 E-post: [email protected] Om Hansa Biopharma 2021-04-08 · LUND, Sweden, April 8, 2021 /PRNewswire/ -- Hansa Biopharma AB "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced the release of Antalet röster i Hansa Biopharma uppgår per dagens datum till 44 615 597,7 och aktiekapitalet uppgår till 45 894 909 kronor.

Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com. Rolf Gulliksen, Head of Corporate Communications Hansa Biopharma Mobil: +46 (0) 733-32 86 34 E-post: rolf.gulliksen@hansabiopharma.com. Om Hansa Biopharma Hansa Biopharma drar nytta av sin unika och patenterade

29 Mar. Regulatory press release. Hansa Biopharma enters preclinical research collaboration with argenx. 01 Mar. Hansa Biopharma appoints Dr. Magnus Korsgren as Head of Research & Development Lund, Sweden April 9, 2021 Hansa Biopharma AB (publ), Reg. No. 556734-5359, with registered office in Lund, gives notice to Annual General Meeting on Wednesday May 12, 2021. In order to mitigate the spread of Covid-19, the Board of Directors has decided that the Annual General Meeting will be conducted by advance voting only, without physical presence of shareholders, proxies and third parties Investor Relations Contact.

Anne Säfström Lanner. Senior Vice President, ©2021 Hansa Biopharma. Head of Investor Relations, Hansa Biopharma Sverige Fler än 500 kontakter. Gå med för att skapa kontakt Hansa Biopharma. MIT Sloan School of Head of Investor Relations. klaus.sindahl@hansabiopharma.com.